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Thisreview will focus onrecent advances inthe application ofantiepidermal growth factor receptor (anti-EGFR)for thetreatment
of breast cancer. The choice of EGFR, a member of the ErbB tyrosine kinase receptor family, stems from evidence pinpointing its
role in various anti-EGFR therapies. Therefore, an increase in our understanding of EGFR mechanism and signaling might reveal
novel targets amenable to intervention in the clinic. This knowledge base might also improve existing medical treatment options
and identify research gaps in the design of new therapeutic agents. While the approved use of drugs like the dual kinase inhibitor
Lapatinib represents signiﬁcant advances in the clinical management of breast cancer, conﬁrmatory studies must be considered to
foster the use of anti-EGFR therapies including safety, pharmacokinetics, and clinical eﬃcacy.
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1.Introduction
Despite the availability of a new array of biomarkers
and a widely adapted clinically relevant/treatment-oriented
approach of classifying breast cancer cases over the last
decade, categorization of breast cancer is an ongoing
challenge which is being revisited more frequently by the
scientiﬁc community. The goal is to ﬁne-tune the diagnostic
assignment of breast cancer cases with the hope that this will
adequately address and improve the eﬀectiveness of selecting
treatment modalities, particularly in regard to the choice of
use of monoclonal antibodies (MoAbs) and small molecule
tyrosine kinase inhibitors (smTKIs) against EGFR, a clinical
strategy collectively referred to as anti-EGFR therapy. EGFR
is a member of the ErbB/HER family of tyrosine kinase
receptors, which also includes its well-documented family
member ErbB2, clinically referred to as HER-2/neu. Anti-
EGFR therapy has found application for cases from all three
major breast cancer subclasses, respectively, the hormone-
sensitive/insensitive group, the ER+/− and HER-2/neu+/−
groups, and the basal-like/triple negative (−)gr o u p .O fn o t e ,
HER-2/neu may also be a genetic biomarker since it has a
more signiﬁcant correlation with a selective HER-2 (+ve)
population of breast cancer cases than EGFR. Preliminary
studies show that anti-EGFR therapy has moderate clinical
eﬃcacy not only on EGFR-expressing cells, but on HER-
2-expressing and -overexpressing cells as well, suggesting
that the treatment outcome may depend on the expression
and responsiveness of the heterodimerization of HER-2 with
EGFR. Although both EGFR and HER-2 (+ve) are favored
biomarkers of eﬃcacy in many ongoing anti-EGFR clinical
studies, their expression is not suﬃciently robust as a prog-
nosticator for clinical outcomes and should not be singularly
used as a criterion for evaluating the responsiveness of breast
cancer cases to anti-EGFR treatment regimens [1]. Tumor
targets for anti-EGFR therapy include early and advanced
stage,andmetastaticbreastcanceraswellasanarrayofother
solidtumorsthatarenotpartofthisreview;datafromrecent
studies suggest that various anti-EGFR/TKI combinations
may not only treat but also lower progression rates of these
forms of cancer.
The primary focus of this article is to review and
summarize recent advances in anti-EGFR therapies in order
to generate a clinically relevant proﬁling system; a com-
plementary objective is to relate the structure of EGFR
with its downstream signaling mechanisms particularly
in the context of inhibition by administered anti-EGFR
therapies. Database search engines like MEDLINE, PubMed,
Scopus, and ENTREZ were used, and the articles were
selected according to the criteria: (i) anti-EGFR therapy2 Journal of Oncology
and clinical eﬃcacy in breast cancer, (ii) publications
from 1998–2008, and (iii) using reviews/conferences/special
reports/randomized clinical trials/phase II and III tri-
als/general research articles. It is hoped that reviews like
this can help to elucidate the mechanisms involved in anti-
EGFR therapy as well as deﬁne relationships between the
overexpression of EGFR and other biomarkers of breast
cancer. Recent data regarding responsiveness to combination
and multiregiment chemotherapies may also provide insight
on the mechanism and activity of anti-EGFR therapies,
speciﬁcally that of the dual kinase inhibitor, Lapatinib
(GW572016), which is capable of targeting both the EGFR
and HER-2/neu tyrosine kinases that are often overexpressed
in breast cancer cells [4].
2.EGFRandIts Role inBreastCancer
EGFR is a member of the EGFR/ErbB/HER family of
Type I transmembrane tyrosine kinase receptors, which
includes ErbB1/HER-1 (EGFR itself), ErbB2/HER-2/neu,
ErbB3/HER-3, and ErbB4/HER-4. The ErbB receptors play
an essential role in organ development and growth by
regulating both the diﬀerentiation and morphology of cells
and tissues. However, speciﬁc members, most notably EGFR,
are frequently overexpressed, and this aberrant expression
and the signaling event it elicits induce erroneous develop-
ment and unrestricted proliferation in a number of human
malignancies including breast cancer [5]. Members of the
ErbB gene family, respectively, ErbB1, ErbB3, and ErbB4 can
be activated by various growth factor ligands, for example,
the epidermal growth factor (EGF). In contrast, no known
ligand has been demonstrated for ErbB2/HER-2/neu, despite
that it still plays an integral role in several signaling pathways
as well as tumorigenesis. Activation of EGFR inevitably
involves homo- or heterodimerization of EGFR with another
EGFR molecule, or a diﬀerent member of the ErbB family
(e.g., HER-2), which in turn induces the ampliﬁed signaling
cascade (Figure 1). Increased activation of EGFR and/or
HER-2 will eventually result in uncontrolled proliferation,
a hallmark of cancer cells. Additionally, the cells harbor-
ing overexpressed EGFR or improper regulation of EGFR
activation may decrease apoptosis, increase metastasis and
even angiogenesis. Dysfunctional EGFR-signaling networks
are reportedly present in a cohort of breast carcinomas with
poor prognosis [5, 6].
To better understand the role of EGFR in breast carcino-
genesis, the aforementioned relationship will be analyzed in
several parts. First, it is important to thoroughly investigate
thesignaling pathway and mechanism of EGFR to properly
examinethecorrelationthatexistsbetweenbreastcancerand
anomalous EGFR expression; in this case, scrutiny of the
structure of EGFR and the role it plays in cell signaling is
imperative. Secondly, anti-EGFR therapies for breast cancer
either in ongoing clinical phase testing or already FDA-
approved are reviewed or summarized in the tables, with
focus directed to speciﬁc developments and progress in
clinical eﬃcacy in recent years. Examples discussed in detail
in Section 3 include Cetuximab, a monoclonal antibody
against EGFR and the most widely used anti-EGFR therapy
in solid tumor treatment regimens; Lapatinib, an innovative
small molecule tyrosine kinase inhibitor of EGFR with a
unique dual-TKI inhibitory activity against both EGFR and
HER-2/neu, which shows improved clinical eﬃcacy and has
heightened the expectation for new breast cancer therapies.
Althoughmanyrecentstudieshavedemonstratedabeneﬁcial
role of Lapatinib used in combination with anti-EGFR
t h e r a p y ,o n l ys e l e c t e de x a m p l e sw i l lb er e v i e w e dt oi l l u s t r a t e
how Lapatinib may be strategically explored to improve
our understanding of the synergy resulting from its use
associated with anti-EGFR therapy.
2.1. EGFR Structure and Signaling Pathway Mechanism.
The EGFR and the activated signaling cascades it elicits
play an integral role in the mechanism and eﬃcacy of
anti-EGFR therapies (Figure 1). Examination of the EGFR
structure (Figure 2) provides a contextual framework for
the inception and development of two major strategies
of anti-EGFR therapy, respectively, anti-EGFR monoclonal
antibodies and small molecule tyrosine kinase inhibitors
(smTKIs). Examples of monoclonal antibodies for EGFR are
found in Cetuximab and Trastuzumab. Anti-EGFR drugs
belonging to smTKIs and in clinical trials include Erlotinib,
Lapatinib, and Geﬁtinib.
2.1.1. Molecular Analysis of EGFR Structure
(1) Ectodomain: Ligand-Binding Domain. Domains I–IV
make up the EGFR ectodomain, a 621-kDa structure
responsible for ligand binding and dimerization, both of
which are considered molecular antecedents for the induced
conformational changes required for the activation of the
internaltyrosinekinase.AlthoughtheEGFRectodomainwas
ﬁrst crystallized in 1998, the detailed structure of the EGFR
ectodomain dimer bound to ligand EGF was not resolved
until 2002 and provided information on a completely novel
and unexpected mode of activation for the EGFR signaling
pathway involving the dimerization process [2, 7–9].
Domain I or L1 (where L: leucine-rich domain) shares
sequence and structural homology with the Domain III or
L2, both of which are involved in ligand binding based on
sitedirectedmutagenesisanddeletion mutationstudies[10].
Domains II and IV, also referred to CR1 and CR2 reﬂecting
their high content of cysteine residues and the potential
for forming intradomain disulﬁde bonds, are important in
facilitating the overall conformational change induced by
binding of the ligand to EGFR. The CR1 also contains a
“protruding loop” capable of bending in a relatively straight,
ligand-binding site of EGFR (Figure 2(b)). This ﬂexible
molecular feature presumably enables binding of the ligand
between the two L domains and at the same time permits
contacts to be made with the “protruding loops” in CR1.
(2) Transmembrane and Juxtamembrane Domains. The
transmembrane domain consists of 23 amino acids and
plays an important role in anchoring the receptor to
the lipid bilayer of the cell. More than 50% of theJournal of Oncology 3
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Figure 1: The EGFR Signaling Pathway. (a) Upon EGF-ligand binding to the EGFR there is subsequent dimerization (homo- or hetero-)
andtyrosinekinaseresidueauto-/transphosphorylationofdimerpartners,whichinturninitiatestheactualdownstreamsignalingpathways.
(b) Ras signaling cascade in tabulated form. (c) PI3K signaling cascade in tabulated form.
transmembrane domain is localized in caveolae or lipid rafts
[10], through posttranslational modiﬁcations, such as N-
linked glycosylation, resulting in enrichment of EGFR in
deﬁned locality of the membrane and hence faster receptor
dimerization following binding of the ligand [11]. Adjacent
to the transmembrane domain facing intracellularly is
the juxtamembrane domain which is believed to regulate
various functional aspects of EGFR including control of the
tyrosine kinase activity, downregulation of the EGFR, ligand
internalization, and receptor sorting. Of note, this domain
also has binding motifs that allow it to interact with second
messengers like calmodulin [10].
(3) Tyrosine Kinase Domain. The tyrosine kinase domain
(TKD) is essential for the functional activation of the recep-
tor and consequently the induction of the EGFR signaling
pathways for the control of cell division and proliferation.
The TKD has a bilobate arrangement marked by an N-
lobe, an activation loop, and a C-lobe [3]. This molecular
conﬁguration accommodates binding of the substrate and
ATP at the active site, enabling substrate phosphorylation
to occur in concomitance with the hydrolysis of ATP
(Figure 2(c)). The TKD contains important tyrosine (Y)
residues that can assume various states of phosphoryla-
tion/dephosphorylation. Knockdown or deletion studies of
the ectodomain suggest that it regulates the dimerization as
well as prevent constitutive activation of the tyrosine kinase.
Binding of the ligand to the ectodomain relieves some of the
steric hindrances normally imposed on the tyrosine kinase
activity, resulting in activation. Site-directed mutagenesis or
deletion analysis in the TKD shows that it is involved in
EGFR dimerization, auto- and transphosphorylation and
also activation of the signaling cascades, all of which have4 Journal of Oncology
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Figure 2: (a) Basic Structure of EGFR demonstrating relevant domains. (I) The extracellular domains: (1) domain I: L1; (2) domain II: CR1;
domain III: L2; domain IV: CR2. (II) Transmembrane domains. (III) The intracellular domains (1) juxtamembrane domain; (2) tyrosine
kinase domain; (3) regulatory region domain. The phosphorylation of several substrates by the tyrosine kinase domain of the EGFR receptor
is responsible for activating the various signaling cascades seen in Figure 1.( b )Structure of domains I–IV of EGFR (no ligand bound). Note
the “protruding loop” in domain II (CR1) directed away from the C-shaped region of the ligand-binding zone formed by domains I, II, and
III. (c) The tyrosine kinase domain of EGFR showing the N-lobe and C-lobe ﬂanking the activation loop and active site cleft [2, 3].
beenexploitedinthedevelopmentofsmallmoleculetyrosine
kinase inhibitors (smTKIs) for targeting EGFR in various
cancer types including breast cancer.
(4) The Activation Loop, Active Site, and C-Terminal Tail
Regions of EGFR. The activation loop of the tyrosine kinase
of EGFR is quite distinct from other receptors harboring
tyrosine kinases. Namely, whereas most receptor TKDs
require phosphorylation for tyrosine kinase activation, this
does not appear to be the case in EGFR. For example,
the phosphorylation of Tyr845 has little aﬀect on the
EGFR kinase activity [3], possibly due to a conformational
arrangement that directs the activation loop away from
the active site rendering it refractory to the state of phos-
phorylation of the receptor tyrosine kinase. Activation of
the EGFR tyrosine kinase phosphorylates numerous targets,
including itself (autophosphorylation), a diﬀerent EGFR
(homodimerization), HER-2/neu of the ErbB gene family
(heterodimerization), and nonreceptor substrates such as
Grb2/SOS, STATs, PLC, and/or PI3K, which in turn initiate
the signaling cascades of MAPK/ERK, STAT, PIP2,a n dA K T ,
respectively. Not surprisingly, therefore, mutations in this
region can cause a substantial decrease in kinase activity,
an outcome considered desirable in cancer therapy and may
underlie the therapeutic eﬃcacy of smTKIs. By binding to
the TKD of EGFR, smTKIs may act by sterically interfering
with the binding of both the substrate and ATP necessary for
phosphorylation, resulting in an overall decreased signaling
activity of the EGFR.
Lastly, it is important to mention that the tyrosine
kinase activity of EGFR is tightly regulated via its own
internal regulatory region located at the C-terminal tail of
thestructure,whichinvolvesthetyrosineresidueclusterwith
the potential of being transphosphorylated during EGFR-
dimerization. It is noteworthy that EGFR dimerization
induces phosphorylation of several tyrosine residues includ-
ing Tyr1069 Tyr1092 Tyr1110 Tyr1116 Tyr1172 Tyr1197, creatingJournal of Oncology 5
docking sites for the recruitment of other adaptor molecules
and signaling proteins. These attributes suggest that the
tyrosine-rich C-terminal tail is a phosphorylable, mobile
structure connected to a relatively stationary TKD.
In summary, the EGFR may be divided into two func-
tionalsubstructures.Theﬁrstoneconsistsoftheextracellular
ectodomain responsible for ligand binding, dimerization,
and the initiation of signal transduction. The ectodomain
has been the thematic target of anti-EGFR therapy, vis-` a-
vis, development of monoclonal antibody directed at the
ligand binding region, which inactivates EGFR through
competitive inhibition of ligand binding, as well as by
inducing overall downregulation of EGFR through increased
receptor internalization. Examples include the monoclonal
antibodies like Cetuximab and Trastuzumab, which play an
extremely critical role in anti-EGFR therapy. Currently, both
these two drugs and Panitumumab are the only anti-EGFR
monoclonal antibodies approved by the FDA for use in the
clinic. The second major functional substructure of EGFR is
the tyrosine kinase domain located on the intracellular side
of the plasma membrane. This domain plays a key role in the
activation of signaling cascades involved in cell proliferation,
division, and diﬀerentiation; therefore, inhibition of the
tyrosine kinase enzymatic activity of EGFR using small
molecule TKIs is a clinically relevant treatment option for
breast cancer patients.
2.2. Breast Cancer and the Signaling Mechanism of EGFR.
As a member of the ErbB receptor family, the EGFR plays
important roles in cell signaling, proliferation, diﬀeren-
tiation, and apoptosis. Signaling is initiated by binding
of ligands to the extracellular domain of the EGFR. Six
well-characterized ligands of EGFR have been identiﬁed,
respectively, EGF, transforming growth factor-α (TGFα),
amphiregulin, heparin binding EGF-like growth factor,
betacellulin, and epiregulin. Ligand binding induces con-
formational change resulting in heterodimerization and the
activation of the major signaling pathways seen in Figure 1.
2.2.1. Statistics and Etiology of Breast Carcinogenesis. Breast
cancer is the most common cancer and a major cause of
morbidity and premature loss of life in women worldwide,
accounting for approximately 7% of all cancer-related deaths
[12]. The highest rates of breast cancer in the world are
seen in the United States, where approximately 1 out of
every 8 women will develop invasive breast cancer, which
is responsible for almost 3% of all deaths in American
women [13]. Given the grim statistics, the need for more
sensitive and reliable detection methods is obvious. Equally
urgentaretreatmentmodalitiesthataremodestincost,easily
compliant, eﬀective, have low to no toxicities, and capable
of targeting the multifaceted and heterogeneous nature of
breast carcinogenesis.
Currently, there is still lack of understanding of the
natural history of breast cancer. It had been hypothesized
thatlobularcarcinomainsitu(LCIS)representedaprecursor
lesion of invasive cancer, and, based on this, mastectomy was
initially recommended [14]. Later studies have shown that
the risk of subsequent breast cancer is bilateral. Moreover, it
became evident that LCIS is not a premalignant lesion, but
rather a marker that identiﬁes women at an increased risk
for subsequent development of invasive breast cancer, with
the risk remaining elevated even beyond two decades. In a
large prospective study from the National Surgical Adjuvant
Breast and Bowel Project involving a 5-year follow-up of 182
women with LCIS managed with excisional biopsy alone,
eight women developed ipsilateral breast tumors (four with
invasive tumors), and three women developed contralateral
breast tumors (two with invasive tumors) [15]. Therefore, it
remains unclear whether or not LCIS progresses to ductal
carcinoma in situ (DCIS) during breast carcinogenesis.
On the other hand, DCIS is a bona ﬁde precursor for
invasive ductal carcinoma and lacks estrogen receptor (ER)
expression. Furthermore, DCIS frequently overexpresses
mutatedp53,HER-2/neu,andEGFR,allofwhichshowsome
clinical correlation with resistance to hormone therapy and
increased risk for the development of invasive, metastatic
breast cancer. Patients with ER(+ve)/PR(+ve) disease usually
respond more favorably to hormonal therapy (as compared
to individuals with ER(−ve)/PR(−ve) status), presumably
in part due to the overexpression of HER-2 and EGFR in
ER(−ve) cells that provide “acquired growth stimulation
autonomy.” These ﬁndings suggest that strategies cotargeting
HER-2 and EGFR expression or their functions might
have therapeutic and preventive potentials particularly in
ER(−ve) breast carcinoma cases.
2.2.2. Expression/Function of HER-2/EGFR and Signaling in
Breast Carcinogenesis. The EGFR gene is frequently altered
by gene ampliﬁcation or overexpression at the mRNA and
protein levels in sporadic breast cancer cases. Numerous
polypeptide ligands sharing an EGF-like motif have been
identiﬁed and shown to be capable of inducing EGFR dimer-
ization with diﬀerent kinetics, eliciting signals of variable
durations, and coupled signal transduction to speciﬁc sets
of cytoplasmic proteins. In principle, therefore, this “ligand-
initiated receptor-mediated signaling-executed” molecular
relay system might generate a large combinatorial set of bio-
logical readouts with enormous potential for diversiﬁcation,
ﬁne tuning, and stringent control of cellular functions and
responses. Of note, the HER-2/EGFR has been proposed
to act as a master regulator of a signaling network that
drives breast carcinoma epithelial cell proliferation; HER-
2 gene ampliﬁcation was observed in 92% of breast cancer
specimens and overexpression of HER-2 at the mRNA, and
protein levels have been correlated with cancer virulence,
resistance to therapy, and poor prognosis. As discussed,
each member of the EGFR gene family has a multifunction
structural organization comprised of an extracellular ligand-
binding/interacting domain connected by a transmembrane
span to an intracellular kinase domain. In an uninduced
state, the EGFR is organized such that the autoinhibitory
loops ﬂanking the kinase active site sterically inhibit it from
binding substrates. Binding to ligands induces EGFR homo-
or heterodimerization concomitant with its autoactivation
by a transphosphorylation mechanism involving speciﬁc6 Journal of Oncology
tyrosineresidueslocatedintheintracellulardomain. Inturn,
phosphorylated EGFR undergoes conformational changes
that create additional docking sites for adaptor proteins,
kinases, and intracellular messengers. Therefore, a tightly
regulated, dynamic equilibrium presumably exists between
inhibited, activated, monomeric, and dimeric EGFR in order
for proper cell signaling to ensue. If any one of these
mechanisms goes awry, the results can be fatal to the cell and
often can be fatal to the organism. The same considerations
may well contribute to the observed clinical eﬃcacy or lack
thereof in EGFR-targeted therapies.
The realization that HER-2 is a master regulator of a
signaling network that drives epithelial cell proliferation
identiﬁes this protein as a target for cancer therapy. When
overexpressed, the HER-2 protein may be constitutively
active, that is, signaling from the receptor occurs by a ligand-
independent manner. Under these conditions, growth-
promoting signals may be continuously transmitted into
the cells in the absence of ligand. As a result, multiple
intracellular signal transduction pathways become activated,
resulting in unregulated cell growth and, in some instances,
oncogenic transformation. Figure 1 depicts some of the
signaling pathways elicited in response to ligand binding
to EGFR and either EGFR/EGFR homodimerization or
EGFR/HER-2 heterodimerization reactions. It also demon-
strates the cascade of events resulting in the transmission
of signals into the nucleus and subsequent cell proliferation
and gene activation. The intracellular signaling pathways
of EGFR and HER-2 are thought to involve Ras-MAPK,
and PI3K-, PKC-, NFκB-mediated pathways. Many clinical
trials have observed a poor clinical outcome and shortened
survival time for women whose breast tumors have HER-2
ampliﬁcation. An inverse correlation of ER and HER-2 levels
between ER(+ve) and ER(−ve) breast cancer cells has been
demonstrated,whichprobablyaccountsforthedevelopment
of tamoxifen resistance in breast cancer cells.
2.2.3. Signaling Cross-Talk and Acquisition of Endocrine
Resistance. Multiple lines of evidence implicate breast can-
cer development and progression as under the control
of steroid hormones, in particular estrogens, via their
interaction with estrogen receptors (ERs) and cross-talk of
ER with receptors including EGFR [16–18]. The classical
mechanism of ER signaling involves binding of estrogens
to intracellular ER, triggering a multitude of events that
culminate in altered transcription of estrogen-responsive
genes. In sequence, protein synthesis occurs resulting in
cell proliferation, angiogenesis, breast cancer growth, pro-
gression, and metastasis [19–21]. The ER-induced signaling
mechanism coupled with the fact that well over two thirds of
breast cancers exhibit high expression of ER, have provided
the rationale for preventing and treating breast cancer
by estrogen antagonism, highlighted by the discovery of
tamoxifen. By selectively modulating the ER, tamoxifen is
considered the mainstay of estrogen antagonist therapy and
among the most eﬀective systemic treatmentfor women
with ER-positive breast cancer at all stages today [21]. A
serious obstacle, however, is intrinsicor acquired resistance
to endocrine agents. Manypatients present with primary (de
novo) resistance to endocrinetherapy, despite high tumor
levels of ER, and all patients withadvanced disease eventually
acquire resistance [22].
Whatunderliestherefractorinesstoendocrine therapies?
A number of possible explanations may be considered. For
example, in addition to the aforementioned activation of
intracellular ER for transcription, estrogens have also been
shown to bind membrane-associated ER [20]. Evidence
also exists on ER activation by a ligand-independent but
growth factor-dependent kinase-mediated mechanism [16].
Important contributing factors for resistance to endocrine
therapy include the levels of both ER and ER coregula-
tory proteins, ampliﬁed extra- and intracellular signaling
from growth factor-mediatedpathways, as well as cross-talk
between the ER pathwayand other growth factor and kinase
networks [16–18]. Other mechanisms may involve ampliﬁ-
cation and/or mutations of key proteins involved in cross-
talk, as well induction of promiscuity and/or antagonism to
therapeutic agents through mutational and posttranslational
modiﬁcation events [21]. It is possible that aberrations and
dysfunctions in these and other mechanisms may occur
with increasing frequency during the development of the
endocrine-resistant phenotype. Delineation of the interplay
between the estrogens, ER, and ER cross-talk with receptors
like EGFR will be an important diagnostic and prognostic
objective in anti-EGFR therapy. Similarly, discovery and
development of novel agents that can reverse resistance by
targeting the ER and its downstream signaling events, or
by selective modulation of the ER:EGFR cross-talk might
improve therapeutic response rates.
In summary, identifying the factors and pathways
responsible for endocrine resistance and deﬁning ways to
overcome it are research gaps in need of further study and
will remain important diagnostic and therapeutic challenges
in the continuing war to better manage and treat breast
cancer.
2.2.4. Breast Cancer Treatment Using Multitarget Strategy
Related to HER-2 Signaling. The ampliﬁcation of the HER-
2 gene and overexpression of the HER-2 protein is frequently
observed(10–40%)inhumanbreastcancerpatients[23]and
has been suggested to associate with tumor aggressiveness,
prognosis, and responsiveness to hormonal and cytotoxic
agents. These observations suggest that HER-2 is an appro-
priate target for tumor-speciﬁc therapies, some of which are
listed as follows.
(1) A humanized monoclonal antibody against HER-2,
rhuMAbHER-2 (Trastuzumab), is already approved
for clinical use in the treatment of patients with
metastatic breast cancer. Some forms of HER-2
overexpressing breast tumors can be successfully
treated using antireceptor monoclonal antibodies,
for example, Herceptin. However, because multiple
proteins are involved in growth-signaling pathways,
development of a uniformly active therapy may
be strategically challenging. Herceptin inhibited theJournal of Oncology 7
Table 1: Response criteria and evaluation ratings used in the classiﬁcation of clinical eﬃcacy and safety/toxicity scoring of anti-EGFR
therapies for solid tumors. General classiﬁcation schemes used in review of clinical eﬃcacy and safety, WHO criteria [24].
General classiﬁcation schemes used in review of clinical eﬃcacy and safety:
Objective response and tumor response were evaluated by the WHO Criteria [24].
Adverse events (AEs) were assessed at each cycle using the common toxicity criteria (CTC).
Cardiac failure/cardiac toxicity was graded based on the NYHA classiﬁcation system.
The Cardiac Review and Evaluation Committee (CREC) evaluates cardiac dysfunction.
Factors for clinical eﬃcacy of treatment:
In an intent-to-treat (ITT) population, in order to evaluate the overall response rate of the individual “patient-drug interaction.”
Overall response (OR): complete response (CR) + partial response (PR)
Clinical beneﬁt (CB): complete response (CR) + partial response (PR) + stable disease (SD) ≥ 6m o n t h s
Time-to-disease-progression (TTP): the time from randomization (randomized initiation of drug/therapy.
Treatment regimen to be tested) to “disease-progression” or death (whichever event occurs ﬁrst).
P13K-dependent pathway, and not the MAPK path-
way. Also, blockade of HER-2 function alone with-
out the interception of the committed, associated
downstream events may restrict the eﬀectiveness of
therapeutic interventions.
(2) Tyrosine kinase inhibitors, such as emodin, which
block HER-2 phosphorylation and its intracellular
signaling.
(3) Heat shock protein Hsp90-associated signal inhibi-
tors, which induce degradation of tyrosine kinase
receptors, such as HER-2.
3. Classes of Anti-EGFRTherapy
3.1. Advances in the Clinical Eﬃcacy of Anti-EGFR Therapies
for Breast Cancer Treatment. The race for a successful breast
cancer treatment intensiﬁed during the late 1990s and
2000s, resulting in the development of innovative anti-EGFR
therapies in the last few years including both monoclonal
antibodies (MoAbs) and small molecule tyrosine kinase
inhibitors. To systematically analyze and summarize the
clinical outcome of these anti-EGFR therapies, it is useful
to identify and deﬁne key terms used in clinical trials. The
relevant key terms can be found in various tables presented
below, as appropriate (see Table 1).
3.2. Monoclonal Antibodies
3.2.1. Cetuximab. Cetuximab is the most commonly used
anti-EGFR therapeutic agent for the treatment of solid
tumors. Originally developed for treating colorectal cancer
(primary: CRC & metastatic: mCRC) and squamous cell
carcinoma of the head and neck and not yet approved
as therapy for breast cancer, Cetuximab does provide an
excellent model for the development of new MoAbs that may
one day be used in breast cancer therapy. As a humanized
mouse MoAb similar to others currently in development:
for example, EMD72000 (Matuzumab) and hR3 (Nimo-
tuzumab), Cetuximab diﬀers from fully humanized MoAbs
like Panitumumab, which have a lower incidence of adverse
events (AEs) (e.g., rash, diarrhea) [25]. In addition, although
Panitumumab blocks ligand-binding to EGFR and causes
receptor internalization like humanized Cetuximab, it does
not induce degradation of the receptors [25].
3.2.2. Trastuzumab. Trastuzumab is an anti-HER-2 receptor
humanized MoAb that has shown signiﬁcant clinical beneﬁts
for the treatment of HER-2/neu(+ve) metastatic breast
cancer as a single agent [26]. Phase II study investigated
the clinical eﬃcacy and safety of Trastuzumab monotherapy
given as ﬁrst-line treatment once every 3 weeks in woman
with HER-2(+ve) metastatic breast cancer (MBC). In 105
patients receiving ﬁve cycles of therapy, the overall response
rate was 19% and the clinical beneﬁt rate was 33%. Median
time-to-progression was 3.4 months (range, 0.6 to 23.6
months).In general, the monotherapy was well tolerated
and no signiﬁcant AEs were reported. The most common
treatment-related AEs were only mild-to-moderate rigors
pyrexia, headaches, nausea, and fatigue. Tables 2(a) and 2(b)
show the clinical eﬃcacy and common AEs of Trastuzumab
monotherapy [27].
Trastuzumab has also been shown to improve survival
rates after chemotherapy, speciﬁcally in the Herceptin
Adjuvant (HERA) study [6]. HERA is an international
multicenter-randomized trial comparing 1 or 2 years of
Trastuzumab treatment with observation alone after stan-
dard neoadjuvant or adjuvant chemotherapy in women with
HER-2(+ve) node positive or high-risk node negative breast
cancer. In an intention-to-treat analysis of a total of 5102
patients, the unadjusted hazard ratio for the risk of death
with Trastuzumab compared with observation alone was
0.66 (95% CI 0.47–0.91; P = .0115). Overall, the hazard rates
were lower for Trastuzumab treatment group after 1 year
compared to the observation group [29]. After 1 year of
Trastuzumab treatment, there were 218 disease-free survival
eventsand59deaths,whereas321disease-freesurvivalevents
and 90 deaths occurred in the control group. Patients with
one or more grade 3 or 4 AEs were 11%, however, there were8 Journal of Oncology
Table 2: Part A. Response to ﬁrst-line 3-weekly Trastuzumab
monotherapy from Baselga et al. [27]. CR: Complete response; PR:
Partial response; SD: Stable disease; CBR: Clinical beneﬁt rate; PD:
Progressivedisease;ORR:Overallresponserate;ITT:Intent-to-treat
population. Part B. Most common treatment-related adverse events
(n = 105), adapted from Baselga et al. [27].
(a)
No. of patients
(n = 105)∗
Response No. %
CR 2 2
PR 18 17
SD 53 51†
CRB (CR + PR + SD > 6 months) 35 33
PD 30 29
ORR 20 19†
∗Data missing for 2 patients.
†One patient with best response of SD in the main study period achieved
CR in the 12-month follow-up period. Therefore, in the follow-up analysis,
ORR was 20%.
(b)
No. of patients
Adverse event No. %
Rigors 19 18
Pyrexia 16 15
Headache 11 10
Nausea 10 10
Fatigue 10 10
minimal cardiac AEs in the 1 year Trastuzumab group with
noreporteddeathsrelatedtocardiacfailures.Therefore,one-
year treatment of Trastuzumab after adjuvant chemotherapy
has signiﬁcant overall survival rates and minimal AEs [29].
Trastuzumab in combination with chemotherapeutic
agents, speciﬁcally paclitaxel and anthracycline (Doxoru-
bicin), has shown signiﬁcant increases in response rates and
disease-free progression (See Table 3)[ 27–29]. The combi-
nation prolonged the median time to disease progression
from 4.6 to 7.4 months, increased the overall response
rate from 32 to 50%, extended duration of response from
6.1 to 9.1 months, and improved 1-year survival times
from 68 to 79% compared with chemotherapy alone. The
clinical eﬃcacy of Trastuzumab alone and in combination
with other chemotherapy options is shown in Table 3.T h e
probability ofsurvival wasshown to increase by 25% for25.4
months with Trastuzumab-plus-chemotherapy compared to
just 20.3 months for chemotherapy alone. Therefore, it
appears that Trastuzumab may sensitize cancer cells to other
forms of chemotherapy. AEs were expectedly seen as in other
chemotherapy-treated patients with MBC. Thus, the com-
bination of Trastuzumab with chemotherapy (anthracycline
or paclitaxel) was active for the treatment of patients with
HER-2(+ve) MBC who had not been previously treated for
metastatic disease. As expected, the clinical beneﬁts from the
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Figure 3: Molecular and crystal structures of EGFR inhibitor
Lapatinib and Lapatinib bound and complexed to EGFR ATP-
binding pocket, respectively. (a) Molecular structure of Lapatinib
(CID208908), an EGFR-ErbB2 inhibitor. (b) Overlay of EGFR in
the Lapatinib and Erlotinib complexes. EGFR in the Lapatinib and
Erlotinib structures is shown as red and green ribbons, respectively.
Lapatinib is shown as a yellow space-ﬁlling model. The two
proteins were overlaid based on residues in the COOH-terminal
domain of the kinase. The COOH-terminal in both structures is
CT. Disordered residues in the COOH-terminal tail of EGFR are
indicated by a dashed line. The ﬁgure was prepared using QUANTA
(Accelrys), adapted from Wood et al. [36].
treatment with Trastuzumab only apply to HER-2/neu(+ve)
breast cancer patients, future studies should be designed
using new targeted patient population.
3.3. Tyrosine Kinase Inhibitors
3.3.1. Lapatinib. Lapatinib is a member of the orally active
smallmoleculesthatreversiblyinhibitbothErbB1andErbB2
tyrosine kinases, which consequently leads to the down-
regulation of both the MAPK and PI3K signaling cascades
responsible for cell proliferation and survival, respectively.
As a dual kinase inhibitor, Lapatinib has shown activity in a
number of diﬀerent metastatic and advanced tumor celllines
as well as xenografts and has recently shown positive results
in clinical testing as well (see Figure 3 and Tables 4(a) and
4(b)). Inhibition of ErbB1/EGFR alone using Geﬁtinib and
Erlotinib, examples of anti-ErbB1 smTKIs, has shown mixed
clinical eﬃcacy results for MBC [31]. Recent studies have
demonstrated that it may be advantageous to inhibit ErbB1Journal of Oncology 9
Table 3: Eﬃcacy of Trastuzumab when given in combination with chemotherapy in metastatic breast cancer from Slamon et al. [28].
Tratuzumab + AC
(n = 143)
AC alone
(n = 138)
Trastuzumab
+p a c l i t a x e l
(n = 92)
Paclitaxel alone
(n = 96)
Trastuzumab +
chemotherapy
(n = 235)
Chemotherapy alone
(n = 234)
Median TTP
(months) 7.8 6.1 6.9 3 7.4 4.6
(P = .0004) (P = .0001) (P = .0001)
Response rate (%) 56 42 41 17 50 32
(P = .0197) (P = .0002) (P < .0001)
Median duration
of response
(months)
9.1 6.7 10.5 4.5 9.1 6.1
(P = .0047) (P = .00124) (P = .0002)
Median TTF
(months) 7.2 5.6 5.8 2.9 6.9 4.5
(P = .0014) (P = .0001) (P = .0001)
1-year survival (%) 83 72 72 60 79 68
(P = .0415) (P = .0975) (P = .008)
Median survival
(months) 26.8 22.8 22.8 18.4 25.4 20.3
(P = .025)
AC: Anthracycline; TTP: Time to disease progression; TTF: Time-to-treatment failure.
and ErbB2 simultaneously in those patients overexpressing
theErbB2/HER-2/neugene,whichconstitutesapproximately
25% of all cases of primary breast cancer [32–35]. Interest-
ingly, although both Lapatinib and Erlotinib bind the ATP-
bindingsiteofEGFR,onlyLapatinibdisplaystheuniquedual
kinase inhibitory activity. The molecular underpinning for
the observed diﬀerences awaits further research in the future
[36].
Clinical eﬃcacy and safety of Lapatinib as a monother-
apy has been recently tested for HER-2-ampliﬁed locally
advanced cases or MBC [30]. In a total of 138 patients
treated with Lapatinib for a median of 17.6 weeks, the
overall response rate was 24% and the clinical beneﬁt was
31%. The median time to response was 7.9 weeks, and the
progression-free survival rates at 4 to 6 months were 63%
and 43%, respectively. Response rates and common AEs are
reported in Table 4. The most common AEs were diarrhea,
rash, pruritus, and nausea, which were primarily grade 1 or
2 toxicities. This study supports further use of Lapatinib in
ﬁrst-lineandearly-stageHER-2-overexpressingbreastcancer
patients [30].
Combination therapy involving Lapatinib has had mixed
resultsasof2008.Forexample,despitethefactthatLapatinib
combinationtherapywithCapecitabinehasshownsuccessin
treatmentforHER-2(+ve)advancedbreastcancertreatment,
a subpopulation of patients often reported occurrences of
grade 4 diarrhea, as well as fatigue, headache, and dizziness
[40]. The same study eventually reported a discontinuation
of treatment (of combined Lapatinib-plus-Capecitabine)
due to increased occurrence of AEs in 22 women in the
combination-therapygroup(13%)[40].However,itwasalso
reported that 18 women in the monotherapy group (12%),
also experienced this high frequency of AEs, which appears
to be inconsistent with the safety reports for Lapatinib in
a number of other sources, which report no reports of any
drug-related grade 4 AEs Table 5 [37, 38, 40].
Furthermore, regarding Phase I safety reports for Lap-
atinib, there were also no reports of drug-related interstitial
pneumonitisorcardiacdysfunctionthatwasnormallyfound
to be associated with other forms of ErbB-targeted therapies
[37, 38]. There was still a need for further investigations
regarding the clinical eﬃcacy, safety, and pharmacokinetics
of Lapatinib, and thus these were goals for the Phase II/III
clinical trials for Lapatinib. The most commonly reported
AEs were diarrhea (42%) and rash (31%); diarrhea incidence
increased with increasing dose, whereas rash incidence had
no correlation with dose regimen [37]. Lapatinib is well
tolerated in doses from 500–1600mg once daily [37].
Another study from 2006 investigated the dual kinase
inhibitor activity of Lapatinib in HER-2-overexpressing
b r e a s tc a n c e rc e l l sa sw e l la sr e s p o n s e so fap a n e lo f3 1
characterized human breast cancer cell lines to treatment by
Trastuzumab, including the use of Trastuzumab-conditioned
HER-2(+ve) cell lines [4]. These studies demonstrated
four key observations associated with Lapatinib treatment
in breast cancer. First, they documented that the anti-
proliferative eﬀects of Lapatinib were in fact concentration
dependent and were seen in all breast cancer cell lines. Sec-
ond, they also reported a range of half-maximal inhibitory
concentrations for Lapatinib (IC50), however, the study
demonstrated a signiﬁcant amount of variation among these
values: IC50 = 0.010–18.6μmol/L. Third, these preliminary
data were also representative of long-termin vivo Lapatinib
treatment regiments for breast cancer; this was ascertained10 Journal of Oncology
Table 4: Part A. Patient response rate: Lapatinib dose cohort comparison adapted from Gomez et al. [30]. Stable disease patients who had a
best response of stable disease (i.e., stable disease documented for a minimum of 7 weeks). Clinical beneﬁt response rates include only patients
with a best response of CR, PR, or stable disease for at least 24 weeks. Disease status was assessed by an independent panel using response
evaluation. Criteria in solid tumors (see Section 3.3). CR: Complete response; PR: Partial response. Part B. Patients with drug-related adverse
events that occurred in >10% of patients receiving Lapatinib, Adapted from Gomez et al. [30].
(a)
Dosing regimen
1500mg once daily 500mg twice daily All patients
(n = 69) (n = 69) (N = 138)
Patient response No. % No. % No. %
Best response
C R 000 0 0 0
PR 15 22 18 26 33 24
Stable disease 40 58 31 45 71 51
Progressive disease 8 12 16 23 24 17
U n k n o w n 694 6 1 0 7
Response rate: CR or PR, % 21.7 26.1 23.9
95% CI 12.7 to 33.3 16.3 to 38.1 17.1 to 31.9
Odds ratio 0.8
95% CI 0.3 to 1.9
P .691
(b)
Dosing regimen
1500mg once daily 500mg twice daily All patients
(n = 69) (n = 69) (N = 138)
Adverse event∗ No. % No. % No. %
Diarrhea 24 35 25 36 49 36
Grade 1-2 23 33 22 32 45 33
Grade 3 1 1 3 4 4 3
Rash 19 29 18 26 37 27
Grade 1-2 19 29 17 25 36 26
Grade 3 0 0 1 1 1 1
Pruritus 14 20 11 16 25 18
Grade 1-2 14 20 11 16 25 18
Grade 3 0 0 0 0 0 0
Nausea 9 13 5 7 14 10
Grade 1-2 9 13 4 6 13 9
Grade 3 0 0 1 1 1 1
∗No grade 4 adverse events occurred for these conditions.
using a 77 consecutive-day Lapatinib treatment schedule in
which there was a signiﬁcant reduction in the volume of
human breast cancer xenografts in athymic mice compared
with untreated controls [4]. The reduction in tumor volume
demonstrated in the aforementioned clinical study with
respect to Lapatinib is consistent with the results obtained
in the laboratory setting as well (see Figure 4)[ 37, 38]. Lastly,
they examined the synergistic eﬀects of a combinatorial ther-
apy of Lapatinib-plus-Trastuzumabfor which their results
have indeed provided the preliminary data necessary to
support the rationale for continuing research regarding the
potential of Lapatinib as a combination anti-EGFR therapy
with Trastuzumab in HER-2-overexpressing breast cancer
and in patients with clinical resistance to Trastuzumab [4].
Thus, this review, in agreement with several earlier reports,
supports further investigation of the beneﬁts of Lapatinib
as a ﬁrst-line treatment regimen for early-stage HER-2-
overexpressing breast cancer cell lines as well as its use in
the treatment of both metastatic and locally advanced breast
cancer cases [40].
3.3.2. Erlotinib. Erlotinib treatment is most commonly
found in combination with other chemotherapeutic agents,
including Capecitabine and Docetaxel. A study researchedJournal of Oncology 11
Table 5: Clinical eﬃcacy of Trastuzumab and Lapatinib as monotherapy agents for metastatic breast cancer [26, 27, 30, 39].
Study No. of patients Initial and following dose OR (%) Median TOP and
range (months)
Trastuzumab
Baselga et al. [27] 105 8mg/kg, 6mg/kg triweekly 19 3.4 (range 0.6–23.6)
Cobleigh et al. [26] 222 4mg/kg, 2mg/kg weekly 15 3.1 (range 0–≥28)
Vogel et al. [39] 114 4mg/kg, 2mg/kg weekly 26 3.8 (range 3.3–5.3)
Or 8mg/kg, 4mg/kg weekly
Lapatinib
Gomez et al. [30] 69 1500mg once daily 24 4.4 (range 0.5–23)
Or 500mg twice daily
OR: Overall response rate; TOP: Time to progression.
To date, most lapatinib therapies are still in progress and currently being evaluated.
Table 6:OverallresponseforTrastuzumab,Lapatinib,Erlotinib,andGeﬁtinibcombinationtherapieswithchemotherapeuticagents[34,40–
43].
Study No. of patients Chemotherapy Dose OR (%)
Trastuzumab
Slamon et al. [34] 143 Doxorubicin Trastuzumab (4mg/kg initial dose,
2mg/kgweekly)
56
Doxorubicin (60mg/m2)
92 Paclitaxel Trastuzumab (4mg/kg initial dose,
2mg/kgweekly)
41
Paclitaxel (175mg/m2)
Marty et al. [43] 186 Docetaxel Trastuzumab (4mg/kg initial dose,
2mg/kgweekly)
34
Docetaxel (100mg/m2 triweekly)
Lapatinib
Geyer et al. [40] 163 Capecitabine Lapatinib (1250mg/day) 22∗
Capecitabine (2000mg/m2)
Erlotinib
Twelves et al. [41]2 4 Capecitabine,
docetaxel Erlotinib (100mg/day) 68
Capecitabine (825mg/m2)
Docetaxel (75mg/m2)
Geﬁtinib
Ciardiello et al. [42]4 1 Docetaxel Geftinib (250mg/day) 54
Docetaxel (75mg/m2 or 100mg/m2)
OR: Overall response rate.
∗Study was performed in women with HER2-positive metastatic breast cancer that has progressed after trastuzumab-based therapy.
the additive eﬃcacy of Erlotinib with Capecitabine and Doc-
etaxel [41]. The combined treatment was administered every
3 weeks, with a total of 24 women with MBC; the overall
responseratewas67%.Themostcommontreatment-related
A E sw e r es k i nt o x i c i t i e sa n dd i a r r h e a .T h es e v e r eA E sw e r e
relatively low, but as the Capecitabine/Docetaxel doses were
increased, the rate of grade 3 events also increased. The
tolerability of the regimen has been measured and the group
reported an established dosage of Erlotinib (100mg/day),
Capecitabine (825mg/m2), and Docetaxel (75mg/m2)i n
patients with MBC [41].
3.3.3. Geﬁtinib. Geﬁtinib has oncebeen approved by FDA as
monotherapyforpatientswithlocallyadvancedormetastatic
nonsmall-cell lung cancer (NSCLC) [45]. However, more
recently, Geﬁtinib has been used for the treatment of MBC,
including a Phase II study of Geﬁtinib in combination with
Docetaxel as ﬁrst-line therapy in MBC [42]. In 41 patients,
a response rate of 54% (95% CI 45–75%), a stable disease
response of 14%, and a progressive disease response of 32%
were reported. Grade 3 or 4 toxicities that were observed
included neutropenia (49%), diarrhea (10%), acne-like rash
(5%), and anemia (2%). Overall, the Geﬁtinib and Docetaxel12 Journal of Oncology
Table 7: Eﬃcacy end points in intent-to-treat population, adapted from Geyer et al. [40].
End point
Lapatinib plus
capecitabine
Capecitabine alone Hazard ratio P-value
(N = 163) (N = 161) (95% CI)
Median time to progression—mo 8.4 4.4 0.49 (0.34–0.71) <.001†
Median progression-free survival—mo 8.4 4.1 0.47 (0.33–0.67) <.001†
Overall response—% (95% CI) 22 (16–29) 14 (9–21) .09‡
Complete response—no. (%) 1( <1) 0( 0 )
Partial response—no. (%) 35 (21) 23 (14)
Clinical beneﬁt—no. (%) 44 (27) 29 (18)
Death—no. (%) 36 (22) 35 (22)
End Points are based on evaluation by the independent review committee under blinded conditions.
†The P-value was calculated with the log-rank test.
‡The P-value was calculated with Fisher’s exact test.
combination demonstrated an active and generally well-
tolerated regimen in women with MBC who have not been
previously treated with metastatic disease [42]. Geﬁtinib
seemed very promising in early clinical phase testing for the
treatment of a number of solid tumors, including NSCLC.
However, the FDA recently withdrew Geﬁtinib from its list of
clinically eﬀective therapies for NSCLC, but is still currently
under critical review in Phase II/III clinical studies for breast
cancer: primary, metastatic, and advanced forms.
With respect to ER-HER2/neu cross-talk in ER/HER2/
neu(+ve) breast cancer, Geﬁtinib has demonstrated promis-
ing responses [31]. In a tamoxifen-resistant, HER2-
overexpressing MCF-7 breast cancer cell line, designated
MCF-7/HER2-18, Geﬁtinib pretreatment was shown to
block ER : EGFR receptor cross-talk, reestablish corepressor
complexes with tamoxifen-bound ER on target gene pro-
moters, eliminate tamoxifen agonistic eﬀects, and restore
tamoxifen antitumor activity both in vitro and in vivo [23].
3.4. Combinational Therapies
3.4.1. Lapatinib and Anti-ErbB2 Inhibitors: Trastuzumab.
The results of Lapatinib and Trastuzumab monotherapy and
combined therapy approaches for treating breast cancer are
s u m m a r i z e di nT a b l e s6 and 7. A particular combination
therapy study involved the comparison of Lapatinib-plus-
pAb (where pAb is a rabbit polyclonal antisera gener-
ated by vaccination with a human ErbB2 fusion protein)
and Lapatinib-plus-Trastuzumab [46]. This study showed
that Lapatinib-plus-Trastuzumab combination therapy had
enhanced clinical eﬃcacy compared to both Lapatinib and
Trastuzumab monotherapies but had similar eﬃcacy as
the secondary combination cocktail of Lapatinib-plus-pAb
[46]. The Lapatinib-plus-Trastuzumab combination therapy
also showed both a signiﬁcant downregulation of survivin,
an important prosurvival/antiapoptosis protein, as well as
enhanced apoptosis [46]. These conclusions along with the
information regarding clinical eﬃcacy and AEs in Table 7
provide suﬃcient preliminary evidence supporting this
synergistic cooperation seen in this combination therapy.
It appears that Lapatinib may in fact sensitize the cells to
further treatment with Trastuzumab thereby enhancing the
individual activity of both drugs.
3.4.2. Lapatinib and Capecitabine. Lapatinib combination
therapy with Capecitabine has also shown success in treat-
ment for HER-2(+ve) advanced breast cancer treatment (see
Tables 6 and 7)[ 40]. Patients with HER-2(+ve) MBC who
had progressed after treatment with regimens that included
an anthracycline, a taxene, and Trastuzumab were ran-
domly assigned to receive either Capecitabine alone versus
Capecitabine in combination with Lapatinib. The hazard
ratio for the independently assessed time to progression
was 0.49 (95% CI 0.34 to 0.71; P < .001); the median
time to progression was 8.4 months in the combination
therapy group, whereas 4.4 months in the monotherapy
group. The most common AEs were diarrhea, the hand-foot
syndrome, nausea, vomiting, fatigue, and rash, varying from
grades 1 to 3. In grade 4, diarrhea, fatigue, headache, and
dizziness were reported. Discontinuation of treatment due
to AEs occurred in 22 women in the combination-therapy
group (13%) and in 18 women in the monotherapy group
(12%) [40]. However, as previously indicated, these reports
are refuted by other sources, which claim no grade 4 AEs
and only minor toxicity reports for Lapatinib monotherapy,
but there are no other reviews speciﬁcally regarding further
investigation into the relationship between combinational
therapies of Lapatinib-plus-Capecitabine, if any does in
fact exist, positively or negatively correlated with improved
outcome.
Therefore, in concurrence with combinational therapies,
a major need clearly exists for further research to be done in
this speciﬁc area of anti-EGFR therapy. There is a signiﬁcant
deﬁcit in the hypotheses and models that can critically
evaluate the data reported thus far on most combinational
therapies.
4. Conclusion
Breastcancerisadiseasethatisresponsibleforapproximately
1% of the mortality rate worldwide. The importance of
developing new and improved therapies for its treatmentJournal of Oncology 13
Table 8: Summary of Anti-EGFR therapy agents. The 5 anti-EGFR therapy drugs discussed in this review: these 5 drugs are currently being
used or in clinical phase testing for anti-EGFR therapy of breast cancer. All of these agents are either already being used in the clinical setting
or are in Phase III clinical development.
Drug name Other names for
the drug
Classiﬁcation of
drug
Target receptor(s)
of drug
Special cancer
types and eﬃcacy
Important
comments
Drug
manufacturer
Cetuximab
Erbitux
(humanized form
of the murine
MoAb: C225)
MoAb (chimeric
IgG1) Blocks EGFR;
Al a r g ev a r i e t yo f
solid tumors:
-CRC/mCRC;
-SCCHN;
Most widely used
anti-EGFR
monoclonal
antibody used in
solid tumor
therapy (07/2007)
[44];
ImClone Systems,
Inc., Princeton, NJ.
&N Y ,N Y .
Trastuzumab Herceptin MoAb (human
IgG1) Blocks HER2/neu;
Mostly widely used
MoAb in treating
HER2+
-overexpressing
cases of BC;
Extremely
important drug in
breast cancer;
F. Hoﬀmann-La
Roche Ltd, Basel,
Switzerland.
Erlotinib Tarceva (OSI-774)s m T K I Inhibition of
EGFR;
Solid tumor
therapy:
-Pancreatic cancer;
-NSCLC (recent);
Nothing unique;
Genetech, Inc.,
South San
Fransisco, CA.
Geﬁtinib Iressa (ZD1839) smTKI -
anilinoquinazoline
Inhibition of
EGFR;
Previously used for
NSCLC-currently
w/d by FDA;
Recently
withdrawn by FDA
for treatment of
NSCLC;
AstraZeneca
Pharmaceuticals,
Wilmington, DE.
In clinical phase
testing for BC as
well as other
metastatic &
advanced cancers;
Lapatinib Tykerb
(GW572016) smTKI
Both EGFR and
HER2/neu;
(Dual-TKI Action)
Solid tumor
therapy:
-BC.
Extremely
important smTKI
in current BC
treatment.
Glaxo-Smith-
Kline,
Philadelphia, PA.
MoAb: Monoclonal antibody; EGFR: Epidermal growth factor receptor (ErbB1); HER-2/neu: Human epidermal growth factor receptor 2; smTKI: Small
molecule tyrosine kinase inhibitor; w/d: Withdrawn; NSCLC: Nonsmall cell lung cancer; BC: Breast cancer; CRC: Colorectal cancer; mCRC: Metastatic
colorectal cancer; SCCHN: Squamous cell carcinoma of the head and neck.
is therefore undisputable. Recently, advances in anti-EGFR
therapy have given hope to the development of new breast
cancer therapies with improved speciﬁcity, activity, and
safety.Increasingly,thereisrecognitionandacceptanceofthe
unique role anti-EGFR therapy plays in the armamentarium
of treatment options available to breast cancer patients.
Recently, novel members of this group, such as Lapatinib,
have been brought to the forefront of this research as it not
only is an extremely eﬀective drug in the clinical setting, but
it also serves as an excellent model for the development of
future EGFR and/or HER-2 inhibitors. The novel dual kinase
inhibitor activity of Lapatinib, which displays tyrosine kinase
receptor inhibitory activity against both EGFR and HER-
2, is both exciting and intriguing. The unique activity of
Lapatinib to inhibit both mechanisms of signaling cascades
should be studied extensively in order to improve upon
the current model of tyrosine kinase inhibition and its role
in anti-EGFR therapy. Other drugs with similar activities
to Lapatinib, such as CI-1033, a pan-ErbB tyrosine kinase
inhibitor, should also be studied thoroughly in order to
identify any important similarities between them and to
determine how these crucial factors can perhaps be mod-
iﬁed to enhance their activity in future anti-EGFR drug
prototypes. Other areas of anti-EGFR therapy that should
be investigated include the ability of the various anti-EGFR
therapeutic modalities to sensitize cancer cells to other
forms of chemotherapy originally considered refractory for
an individual patient. This is another extremely important
avenue that should be investigated exhaustively.
Although there is much improvement to be done, the
wealth of knowledge surrounding these therapies continues
to grow (see Table 8). This observation, along with recent
advances in crystallography and docking techniques, the
development of improved high-throughput analyses for
identifying novel anti-EGFR activity, as well as advances
in DNA/RNA-microarray technology used for classiﬁcation
purposes and extremely useful in the clinical setting, all
continue to contribute to the overall understanding and
development of these new treatment regiments as well as
treating breast canceras a whole. The design rationale of new14 Journal of Oncology
(a)
(b)
(c)
Figure 4: Immunohistochemical staining demonstrating the clini-
cal eﬃcacy of Lapatinib. Figure 4 identiﬁes inhibition of activated,
phosphorylated ErbB2/HER-2/neu (p-ErbB2) in a breast cancer
patient responding to Lapatinib treatment. (a) Shows a dermal-
lymphatic invasion (magenta) that is consistent with recurrent
inﬂammatory breast cancer. (b) and (c) Show further immuno-
histochemical staining for p-ErbB2 performed on tumor biopsy
samples obtained from patient X on days 0 (4B) and 21 (4C) of
Lapatinib therapy; note the change in positive staining (brownish-
yellow). There is a signiﬁcant decrease in the activation of p-ErbB2
in response to Lapatinib [37, 38].
anti-EGFRtherapiesliesintheintimaterelationshipbetween
the mechanisms of action of current forms of treatment
and the structure of the EGFR. We believe that meticulous
inspection of the unique intermolecular interactions of these
drugs with this receptorand its family members willnot only
lead to future accomplishments in anti-EGFR therapy but
will also increase insight into chemotherapy as a whole for
breast cancer.
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